1. Home
  2. SNDX vs PL Comparison

SNDX vs PL Comparison

Compare SNDX & PL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • PL
  • Stock Information
  • Founded
  • SNDX 2005
  • PL 2010
  • Country
  • SNDX United States
  • PL United States
  • Employees
  • SNDX N/A
  • PL N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • PL Aerospace
  • Sector
  • SNDX Health Care
  • PL Industrials
  • Exchange
  • SNDX Nasdaq
  • PL Nasdaq
  • Market Cap
  • SNDX 1.1B
  • PL 947.7M
  • IPO Year
  • SNDX 2016
  • PL N/A
  • Fundamental
  • Price
  • SNDX $10.70
  • PL $3.56
  • Analyst Decision
  • SNDX Strong Buy
  • PL Buy
  • Analyst Count
  • SNDX 11
  • PL 11
  • Target Price
  • SNDX $35.91
  • PL $5.53
  • AVG Volume (30 Days)
  • SNDX 2.3M
  • PL 3.0M
  • Earning Date
  • SNDX 05-05-2025
  • PL 06-04-2025
  • Dividend Yield
  • SNDX N/A
  • PL N/A
  • EPS Growth
  • SNDX N/A
  • PL N/A
  • EPS
  • SNDX N/A
  • PL N/A
  • Revenue
  • SNDX $43,722,000.00
  • PL $244,352,000.00
  • Revenue This Year
  • SNDX $263.44
  • PL $14.08
  • Revenue Next Year
  • SNDX $129.44
  • PL $21.49
  • P/E Ratio
  • SNDX N/A
  • PL N/A
  • Revenue Growth
  • SNDX N/A
  • PL 10.72
  • 52 Week Low
  • SNDX $9.66
  • PL $1.67
  • 52 Week High
  • SNDX $25.07
  • PL $6.71
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.98
  • PL 52.59
  • Support Level
  • SNDX $9.67
  • PL $3.38
  • Resistance Level
  • SNDX $14.24
  • PL $3.59
  • Average True Range (ATR)
  • SNDX 0.93
  • PL 0.16
  • MACD
  • SNDX -0.26
  • PL 0.07
  • Stochastic Oscillator
  • SNDX 22.62
  • PL 84.56

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About PL Planet Labs PBC

Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.

Share on Social Networks: